Fiera Capital Corp reduced its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 0.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 372,519 shares of the company’s stock after selling 2,568 shares during the quarter. Fiera Capital Corp […]
TD Asset Management Inc reduced its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 72.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 38,158 shares of the company’s stock after selling 99,494 shares during the quarter. TD Asset Management Inc’s holdings in Neurocrine Biosciences were worth $4,558,000 at the end […]
Canandaigua National Corp trimmed its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 8.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,735 shares of the company’s stock after selling 157 shares during the period. Canandaigua National Corp’s holdings in Neurocrine Biosciences were worth $207,000 as of its most recent filing with […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) – Research analysts at Oppenheimer issued their Q1 2023 earnings estimates for shares of Neurocrine Biosciences in a research report issued on Monday, May 1st. Oppenheimer analyst J. Olson anticipates that the company will post earnings of $0.03 per share for the quarter. The consensus estimate for Neurocrine […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) – Equities researchers at Cantor Fitzgerald issued their FY2023 earnings per share estimates for Neurocrine Biosciences in a report released on Thursday, April 27th. Cantor Fitzgerald analyst C. Duncan forecasts that the company will post earnings per share of $2.55 for the year. Cantor Fitzgerald has a “Overweight” […]